Broncus Holding Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Broncus Holding hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

Rückkaufsrendite

Gesamte Aktionärsrendite	0%
Zukünftige Dividendenrendite	0%
Wachstum der Dividende	n/a
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Ausschüttungsquote	n/a

Jüngste Updates zu Dividenden und Rückkäufen

Keine Aktualisierungen

Recent updates

An Intrinsic Calculation For Broncus Holding Corporation (HKG:2216) Suggests It's 47% Undervalued

Dec 06

Analysts Just Slashed Their Broncus Holding Corporation (HKG:2216) EPS Numbers

Sep 04

Here's Why We're Not Too Worried About Broncus Holding's (HKG:2216) Cash Burn Situation

Jun 21

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von 2216 in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von 2216 gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Broncus Holding Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von 2216 im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (2216)	n/a
Untere 25 % des Marktes (HK)	3.3%
Markt Top 25 % (HK)	8.1%
Branchendurchschnitt (Medical Equipment)	3.4%
Analystenprognose (2216) (bis zu 3 Jahre)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von 2216 im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von 2216 im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von 2216, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da 2216 keine Ausschüttungen gemeldet hat.

Broncus Holding Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Updates zu Dividenden und Rückkäufen

Recent updates

First half 2024 earnings released: US$0.016 loss per share (vs US$0.03 loss in 1H 2023)

Broncus Holding Corporation to Report Q2, 2024 Results on Aug 29, 2024

Broncus Holding Corporation Announces Management Changes

Broncus Holding Corporation Announces Changes to Its Board

Full year 2023 earnings: EPS and revenues miss analyst expectations

Broncus Holding Corporation, Annual General Meeting, May 20, 2024

We Think Broncus Holding (HKG:2216) Needs To Drive Business Growth Carefully

Broncus Holding Corporation to Report Fiscal Year 2023 Results on Mar 28, 2024

Broncus Holding Corporation Announces Resignation of Zhenjun Zi as Non-Executive Director

Broncus Holding (HKG:2216) Is In A Good Position To Deliver On Growth Plans

Broncus Holding Corporation (SEHK:2216) entered into share purchase agreement to acquire Fibernova Holding Corporation from from Zhao and others for $2.7 million.

First half 2023 earnings released: US$0.03 loss per share (vs US$0.033 loss in 1H 2022)

Broncus Holding Corporation Announces Chief Executive Officer Changes, Effective on September 1, 2023

Broncus Holding Corporation Announces Re-Designation of Guowei Zhan from an Executive Director to Non-Executive Director, Effective September 1, 2023

Broncus Holding Corporation to Report First Half, 2023 Results on Aug 29, 2023

Broncus Holding Corporation Completes the First Case of Registered Clinical Trials of Its Targeted Lung Denervation Radiofrequency Ablation System

Will Broncus Holding (HKG:2216) Spend Its Cash Wisely?

Consensus estimates of losses per share improve by 48%

Consensus revenue estimates fall by 36%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Companies Like Broncus Holding (HKG:2216) Are In A Position To Invest In Growth

An Intrinsic Calculation For Broncus Holding Corporation (HKG:2216) Suggests It's 47% Undervalued

Less than half of directors are independent

Broncus Holding Corporation Announces Zhejiang Medical Products Administration Approves Disposable Nebulizing Micro-Catheter for Endoscope for Marketing in China

Consensus forecasts updated

Analysts Just Slashed Their Broncus Holding Corporation (HKG:2216) EPS Numbers

First half 2022 earnings released: US$0.03 loss per share (vs US$0.19 loss in 1H 2021)

Broncus Holding Corporation Announces Board and Executive Changes

Broncus Holding Corporation to Report First Half, 2022 Results on Aug 30, 2022

Consensus EPS estimates fall by 16%

Broncus Holding Corporation Completes Surgeries on the First Group of Patients Using Its InterVapor, the Thermal Vapor Treatment System, After Approved for Marketing in China

Here's Why We're Not Too Worried About Broncus Holding's (HKG:2216) Cash Burn Situation

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Broncus Holding Corporation, Annual General Meeting, May 13, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2024

Broncus Holding Corporation Announces Resignation of Wen Hao Wang as Chief Financial Officer

Non Executive Director recently bought HK$390k worth of stock

Broncus Holding Corporation announces Enrollment for Registered Clinical Trials Successfully Completed for RF-II in China

Broncus Holding Corporation has completed an IPO in the amount of HKD 1.670939 billion.

Less than half of directors are independent

Stabilität und Wachstum des Zahlungsverkehrs

Dividendenrendite im Vergleich zum Markt

Gewinnausschüttung an die Aktionäre

Barausschüttung an die Aktionäre

Entdecken Sie dividendenstarke Unternehmen